Cargando…

Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence

BACKGROUND: Pterygium is very common in India and is usually removed by limbal conjunctival autograft transplantation (LCAT), which, despite being the first-line therapy, is still associated with recurrences of up to 18%. OBJECTIVES: To compare the safety and efficacy of topical cyclosporine A (CsA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Raina, Usha K., Pavitra, Banu, Bhattacharya, Shruti, Ravinesh, Kumar, Goel, Ruchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062085/
https://www.ncbi.nlm.nih.gov/pubmed/37007236
http://dx.doi.org/10.4103/ojo.ojo_56_22
_version_ 1785017424463003648
author Raina, Usha K.
Pavitra, Banu
Bhattacharya, Shruti
Ravinesh, Kumar
Goel, Ruchi
author_facet Raina, Usha K.
Pavitra, Banu
Bhattacharya, Shruti
Ravinesh, Kumar
Goel, Ruchi
author_sort Raina, Usha K.
collection PubMed
description BACKGROUND: Pterygium is very common in India and is usually removed by limbal conjunctival autograft transplantation (LCAT), which, despite being the first-line therapy, is still associated with recurrences of up to 18%. OBJECTIVES: To compare the safety and efficacy of topical cyclosporine A (CsA) and interferon (IFN) alpha-2b in the prevention of postoperative recurrence of pterygium. METHODS: A total of 40 patients with primary pterygium were randomized into two equal groups, Group C and Group I. Both the groups underwent LCAT, with Group C kept on topical cyclosporine 0.05% (CsA) 4 times daily and Group I on topical IFN alpha 2b 0.2 million IU 4 times daily postoperatively for 3 months. Pre- and posttreatment best-corrected visual acuity (BCVA), recurrence, and complications were assessed at day 1, week 1, 1 month, and 3 months. RESULTS: The mean preoperative BCVA of 0.51 ± 0.18 and 0.51 ± 0.23 improved to 0.13 ± 0.13 and 0.13 ± 0.13 in Group C and Group I, respectively, after 3 months of treatment (P < 0.0001). Recurrence was seen in 2 cases in Group C and in 1 case in Group I at 3 months. No significant complications occurred in either of the groups. CONCLUSION: Topical CsA and IFN Alpha-2b are newer efficacious adjuvants with LCAT for prevention of postoperative pterygium recurrence.
format Online
Article
Text
id pubmed-10062085
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-100620852023-03-31 Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence Raina, Usha K. Pavitra, Banu Bhattacharya, Shruti Ravinesh, Kumar Goel, Ruchi Oman J Ophthalmol Original Article BACKGROUND: Pterygium is very common in India and is usually removed by limbal conjunctival autograft transplantation (LCAT), which, despite being the first-line therapy, is still associated with recurrences of up to 18%. OBJECTIVES: To compare the safety and efficacy of topical cyclosporine A (CsA) and interferon (IFN) alpha-2b in the prevention of postoperative recurrence of pterygium. METHODS: A total of 40 patients with primary pterygium were randomized into two equal groups, Group C and Group I. Both the groups underwent LCAT, with Group C kept on topical cyclosporine 0.05% (CsA) 4 times daily and Group I on topical IFN alpha 2b 0.2 million IU 4 times daily postoperatively for 3 months. Pre- and posttreatment best-corrected visual acuity (BCVA), recurrence, and complications were assessed at day 1, week 1, 1 month, and 3 months. RESULTS: The mean preoperative BCVA of 0.51 ± 0.18 and 0.51 ± 0.23 improved to 0.13 ± 0.13 and 0.13 ± 0.13 in Group C and Group I, respectively, after 3 months of treatment (P < 0.0001). Recurrence was seen in 2 cases in Group C and in 1 case in Group I at 3 months. No significant complications occurred in either of the groups. CONCLUSION: Topical CsA and IFN Alpha-2b are newer efficacious adjuvants with LCAT for prevention of postoperative pterygium recurrence. Wolters Kluwer - Medknow 2023-02-21 /pmc/articles/PMC10062085/ /pubmed/37007236 http://dx.doi.org/10.4103/ojo.ojo_56_22 Text en Copyright: © 2023 Oman Ophthalmic Society https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Raina, Usha K.
Pavitra, Banu
Bhattacharya, Shruti
Ravinesh, Kumar
Goel, Ruchi
Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence
title Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence
title_full Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence
title_fullStr Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence
title_full_unstemmed Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence
title_short Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence
title_sort topical cyclosporine a and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062085/
https://www.ncbi.nlm.nih.gov/pubmed/37007236
http://dx.doi.org/10.4103/ojo.ojo_56_22
work_keys_str_mv AT rainaushak topicalcyclosporineaandinterferonalpha2basadjuvantstosurgerytodecreasepterygiumrecurrence
AT pavitrabanu topicalcyclosporineaandinterferonalpha2basadjuvantstosurgerytodecreasepterygiumrecurrence
AT bhattacharyashruti topicalcyclosporineaandinterferonalpha2basadjuvantstosurgerytodecreasepterygiumrecurrence
AT ravineshkumar topicalcyclosporineaandinterferonalpha2basadjuvantstosurgerytodecreasepterygiumrecurrence
AT goelruchi topicalcyclosporineaandinterferonalpha2basadjuvantstosurgerytodecreasepterygiumrecurrence